针对胰岛素样生长因子是否有益或有害？：肿瘤学家的观点。
Will targeting insulin growth factor help us or hurt us?: An oncologist's perspective.
机构信息
Molecular Radiation Oncology Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States.
出版信息
Ageing Res Rev. 2011 Jan;10(1):62-70. doi: 10.1016/j.arr.2009.10.007. Epub 2009 Nov 5.
The insulin/insulin growth factor (IGF) pathway is a critical mediator of longevity and aging. Efforts to extend longevity by altering the insulin/IGF pathway may have varying effects on other physiological processes. Reduced insulin/IGF levels may decrease the incidence of certain cancers as well as the risk of developing metastatic disease. However, it may also increase the risk of developing cardiovascular disease as well as cardiovascular related mortality. Pursuing the right insulin/IGF pathway targets will require striking a balance between inhibiting cancer cell development and progression and avoiding damage to tissues under normal insulin/IGF-mediated control. This review will discuss the roles of the insulin/IGF pathway in aging and longevity and the development of cancer cell metastasis and considerations in taking insulin/IGF directed targets to the oncology clinic.
胰岛素/胰岛素样生长因子（IGF）通路是长寿和衰老的关键调节因子。通过改变胰岛素/IGF 通路来延长寿命的努力可能会对其他生理过程产生不同的影响。降低胰岛素/IGF 水平可能会降低某些癌症的发病率以及发生转移性疾病的风险。然而，它也可能增加患心血管疾病以及心血管相关死亡率的风险。在抑制癌细胞的发展和进展与避免正常胰岛素/IGF 介导控制下的组织损伤之间取得平衡，将需要寻求正确的胰岛素/IGF 通路靶标。这篇综述将讨论胰岛素/IGF 通路在衰老和长寿中的作用，以及癌细胞转移的发展，并考虑将胰岛素/IGF 靶向药物应用于肿瘤临床。
Zotero 插件